 |
|
Effect of Nonoxynol-9 Gel on Urogenital Gonorrhea and Chlamydial Infection
A Randomized Controlled Trial
Ronald E. Roddy, MPH;
Léopold Zekeng, PhD;
Kelley A. Ryan, BA;
Ubald Tamoufé, MSc;
Kathryn G. Tweedy, MSc
JAMA. 2002;287:1117-1122.
Context Nonoxynol-9 has been suggested as a vaginal microbicide to protect against common sexually transmitted infections.
Objective To compare nonoxynol-9 gel and condom use (gel group) vs condom use alone (condom group) for the prevention of male-to-female transmission of urogenital gonococcal and chlamydial infection.
Design and Setting Randomized controlled trial conducted at 10 community clinics and 10 pharmacies in Yaoundé, Cameroon, between October 1998 and September 2000, with 6 months of follow-up.
Participants High-risk population of 1251 women (excluding sex workers) being treated for or who had symptoms of sexually transmitted infections. Three were excluded from the gel group (0.5%) and 7 from the condom group (1%) because of no follow-up data.
Interventions Nonoxynol-9 gel (100 mg) and condoms or condoms only.
Main Outcome Measure A positive test result for gonococcal or chlamydial infection by the ligase chain reaction assay; secondary outcome measure was a positive test result for human immunodeficiency virus (HIV).
Results The rate ratio (RR) for new urogenital infections was 1.2 for the gel group vs condom group (95% confidence interval [CI], 0.9-1.6; P = .21). The gel group had 116 diagnosed gonococcal infections, chlamydial infections, or both for a rate of 43.6 per 100 person-years, and the condom group had 100 infections for a rate of 36.6 per 100 person-years. The RR for gonococcal infection in the gel group vs the condom group was 1.5 (95% CI, 1.0-2.3) and for chlamydial infection was 1.0 (95% CI, 0.7-1.4). There were 5 new cases of HIV infections in the gel group and 4 in the condom group. Three women in each group became pregnant during the study.
Conclusion Nonoxynol-9 gel did not protect against urogenital gonococcal or chlamydial infection.
Author Affiliations: Family Health International, Durham, NC (Mr Roddy and Mss Ryan and Tweedy); Laboratoire de Santé Hygiène Mobile, Ministry of Public Health (Dr Zekeng), and Care and Health Program (Mr Tamoufé), Yaoundé, Cameroon.
RELATED ARTICLES
Nonoxynol-9 as a Vaginal Microbicide for Prevention of Sexually Transmitted Infections: It's Time to Move On
Barbra A. Richardson
JAMA. 2002;287(9):1171-1172.
EXTRACT
| FULL TEXT
March 6, 2002
JAMA. 2002;287(9):1193-1194.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Male Contraception
Anderson and Baird
Endocr. Rev. 2002;23:735-762.
ABSTRACT
| FULL TEXT
Nonoxynol-9 Spermicide Contraception Use--United States, 1999
JAMA 2002;287:2938-2939.
FULL TEXT
Nonoxynol-9 Gel Does Not Protect Against Gonorrhea or Chlamydia
JWatch Emergency Med. 2002;2002:10-10.
FULL TEXT
Condoms Are Best for STI Protection: Nonoxynol-9 May Not Add Benefit
JWatch Women's Health 2002;2002:2-2.
FULL TEXT
Nonoxynol-9 as a Vaginal Microbicide for Prevention of Sexually Transmitted Infections: It's Time to Move On
Richardson
JAMA 2002;287:1171-1172.
FULL TEXT
|
